These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25569733)

  • 1. Risk for colorectal neoplasia in patients with inflammatory bowel disease and mucosa indefinite for dysplasia.
    Lai KK; Horvath B; Xie H; Wu X; Lewis BL; Pai RK; Plesec T; Patil DT; Gordon IO; Wang Y; Shen B; Goldblum JR; Liu X
    Inflamm Bowel Dis; 2015 Feb; 21(2):378-84. PubMed ID: 25569733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis.
    Pekow JR; Hetzel JT; Rothe JA; Hanauer SB; Turner JR; Hart J; Noffsinger A; Huo D; Rubin DT
    Inflamm Bowel Dis; 2010 Aug; 16(8):1352-6. PubMed ID: 20027656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Indefinite Dysplasia and Advanced Neoplasia in Patients With Inflammatory Bowel Diseases Undergoing Surveillance.
    Mahmoud R; Shah SC; Torres J; Castaneda D; Glass J; Elman J; Kumar A; Axelrad J; Harpaz N; Ullman T; Colombel JF; Oldenburg B; Itzkowitz SH
    Clin Gastroenterol Hepatol; 2020 Jun; 18(7):1518-1527.e3. PubMed ID: 31446183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prior colorectal neoplasia is associated with increased risk of ileoanal pouch neoplasia in patients with inflammatory bowel disease.
    Derikx LA; Kievit W; Drenth JP; de Jong DJ; Ponsioen CY; Oldenburg B; van der Meulen-de Jong AE; Dijkstra G; Grubben MJ; van Laarhoven CJ; Nagtegaal ID; Hoentjen F;
    Gastroenterology; 2014 Jan; 146(1):119-28.e1. PubMed ID: 24076060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nearly a Third of High-Grade Dysplasia and Colorectal Cancer Is Undetected in Patients with Inflammatory Bowel Disease.
    Eluri S; Parian AM; Limketkai BN; Ha CY; Brant SR; Dudley-Brown S; Efron JE; Fang SG; Gearhart SL; Marohn MR; Meltzer SJ; Bashar S; Truta B; Montgomery EA; Lazarev MG
    Dig Dis Sci; 2017 Dec; 62(12):3586-3593. PubMed ID: 28631086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of DNA Flow Cytometric Analysis of Paraffin-embedded Tissue in the Risk Stratification and Management of 'Indefinite for dysplasia' in Patients With Inflammatory Bowel Disease.
    Wen KW; Rabinovitch PS; Wang D; Huang D; Mattis AN; Choi WT
    J Crohns Colitis; 2019 Mar; 13(4):472-481. PubMed ID: 30423034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Misclassification of dysplasia in patients with inflammatory bowel disease: consequences for progression rates to advanced neoplasia.
    van Schaik FD; ten Kate FJ; Offerhaus GJ; Schipper ME; Vleggaar FP; van der Woude CJ; Stokkers PC; de Jong DJ; Hommes DW; van Bodegraven AA; Siersema PD; Oldenburg B;
    Inflamm Bowel Dis; 2011 May; 17(5):1108-16. PubMed ID: 20824815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease.
    Shah SC; Ten Hove JR; Castaneda D; Palmela C; Mooiweer E; Colombel JF; Harpaz N; Ullman TA; van Bodegraven AA; Jansen JM; Mahmmod N; van der Meulen-de Jong AE; Ponsioen CY; van der Woude CJ; Oldenburg B; Itzkowitz SH; Torres J
    Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1106-1113.e3. PubMed ID: 29378311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
    Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
    J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation.
    Cao D; Wilentz RE; Abbruzzese JL; Ho L; Maitra A
    Int J Gastrointest Cancer; 2005; 36(1):39-46. PubMed ID: 16227634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review with meta-analysis: incidence and factors for progression to advanced neoplasia in inflammatory bowel disease patients with indefinite and low-grade dysplasia.
    Wan J; Wang X; Zhang Y; Chen M; Wang M; Wu K; Liang J
    Aliment Pharmacol Ther; 2022 Mar; 55(6):632-644. PubMed ID: 35166389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance.
    Navaneethan U; Jegadeesan R; Gutierrez NG; Venkatesh PG; Hammel JP; Shen B; Kiran RP
    J Crohns Colitis; 2013 Dec; 7(12):e684-91. PubMed ID: 23916526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colorectal cancer risk of flat low-grade dysplasia in inflammatory bowel disease: a systematic review and proportion meta-analysis.
    Lauricella S; Fabris S; Sylla P
    Surg Endosc; 2023 Jan; 37(1):48-61. PubMed ID: 35920906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of "indefinite for dysplasia" in inflammatory bowel disease: correlation with DNA flow cytometry and other risk factors of colorectal cancer.
    Choi WT; Rabinovitch PS; Wang D; Westerhoff M
    Hum Pathol; 2015 Jul; 46(7):939-47. PubMed ID: 25962315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colonic neoplasia in young patients with inflammatory bowel disease and primary sclerosing cholangitis.
    Imam MH; Thackeray EW; Lindor KD
    Colorectal Dis; 2013 Feb; 15(2):198-203. PubMed ID: 22712545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted next-generation sequencing supports serrated epithelial change as an early precursor to inflammatory bowel disease-associated colorectal neoplasia.
    Singhi AD; Waters KM; Makhoul EP; Parian A; Lazarev MG; Proksell SS; Dueker JM; Schwartz MB; Wald AI; Nikiforova MN; Montgomery EA
    Hum Pathol; 2021 Jun; 112():9-19. PubMed ID: 33727167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease course and management strategy of pouch neoplasia in patients with underlying inflammatory bowel diseases.
    Wu XR; Remzi FH; Liu XL; Lian L; Stocchi L; Ashburn J; Shen B
    Inflamm Bowel Dis; 2014 Nov; 20(11):2073-82. PubMed ID: 25137416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal low-grade tubuloglandular adenocarcinoma in inflammatory bowel disease.
    Levi GS; Harpaz N
    Am J Surg Pathol; 2006 Aug; 30(8):1022-9. PubMed ID: 16861975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of p53 predicts colorectal neoplasia risk in patients with inflammatory bowel disease and mucosa changes indefinite for dysplasia.
    Horvath B; Liu G; Wu X; Lai KK; Shen B; Liu X
    Gastroenterol Rep (Oxf); 2015 Nov; 3(4):344-9. PubMed ID: 26063242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.